You are here: vision-research.eu » News
Philippe Valmaggia (Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Department of Ophthalmology, University Hospital Basel, Switzerland), leading scientist of the study “Iris color matters – a contractility analysis with dynamic volume-rendered optical coherence tomography pupillometry” explains the aim and main results of this research project.
In a conversation with Prime News co-editor in chief Oliver Sterchi, Hendrik Scholl talks about opportunities of curing blindness, Switzerland as a research location, and collaboration between academia and industry.
Click here to listen to the podcast (only available in German)
An international team of researchers has found via clinical trial that the drug pegcetacoplan may slow the onset of age-related macular degeneration in some people.
Researchers at the University and the University Hospital of Bonn have developed a method that could be used to diagnose atherosclerosis. Using self-learning software, they were able to identify vascular changes in patients with peripheral arterial disease (PAD), often at an early stage.
Reduced blood flow and impaired neurovascular coupling are well-known features of glaucoma, the main cause of non-curable blindness affecting 80 million people worldwide in 2020. The mechanisms underlying these abnormalities are now unveiled, thanks to new research by a team led by Adriana Di Polo, professor of neuroscience and ophthalmology at Université de Montréal.
Two years ago, a Stanford researcher and his team showed that with a thin, pixelated chip and specially designed glasses, they could restore limited vision in the center of the visual field of patients suffering from macular degeneration. In a recent, follow-up study, the researchers found that this prosthetic vision naturally integrated with the patients' peripheral vision, which was unaffected by the disease.
Authors in low-income countries rarely published free-to-read papers, even when they qualified for publication-fee waivers.
The company completed enrollment ahead of schedule in a second Phase 3 FDA registration trial for Nyxol in RM with top-line results expected by the end of the first quarter.
Mahdi Gouravani, from the Tehran University of Medical Sciences in Iran, and colleagues conducted a meta-analysis to examine choroidal thickness measurements for individuals with migraine and healthy individuals.
Faricimab is noninferior to aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema, according to two studies published in The Lancet.
Aqueous biomarkers could help identify patients with neovascular age-related macular degeneration (nvAMD) who may not require, or who may not benefit from, long-term antivascular endothelial growth factor (VEGF) therapy.
The Toronto-based medical eyewear company partnered with the visual assistance community to help empower an Oregon college student with enhanced vision.
Researchers from the University of California, Irvine have discovered that the absence of Adiponectin receptor 1 protein (AdipoR1), one of the principal enzymes regulating ceramide homeostasis in the retina, leads to an accumulation of ceramides in the retina, resulting in progressive photoreceptor cell death and ultimately vision loss.
Researchers led by Michiko Mandai at the RIKEN Center for Biosystems Dynamics Research (BDR) in Japan have used a genetic modification to improve human-derived retina transplants grown in the lab.
The results of the YOSEMITE and RHINE phase 3 trials that evaluated the efficacy of faricimab (Vabysmo, Genentech) for treating center-involved diabetic macular edema (DME) compared with aflibercept (Eylea, Regeneron Pharmaceuticals) found that after 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.